In Vitro Framework to Assess the Anti-Helicobacter pylori Potential of Lactic Acid Bacteria Secretions as Alternatives to Antibiotics

• Published in: International journal of molecular sciences 2021-05, Vol.22 (11), p.5650
• Main Authors: Whiteside, Samantha A., Mohiuddin, Mahi M., Shlimon, Sargon, Chahal, Jaspreet, MacPherson, Chad W., Jass, Jana, Tompkins, Thomas A., Creuzenet, Carole
• Format: Article
• Language: English
• Subjects: cytokines; Helicobacter pylori; inflammation; lactic acid bacteria; secretome; urease
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22115650

Helicobacter pylori is a prevalent bacterium that can cause gastric ulcers and cancers. Lactic acid bacteria (LAB) ameliorate treatment outcomes against H. pylori, suggesting that they could be a source of bioactive molecules usable as alternatives to current antibiotics for which resistance is mounting. We developed an in vitro framework to compare the anti-H. pylori properties of 25 LAB and their secretions against H. pylori. All studies were done at acidic and neutralized pH, with or without urea to mimic various gastric compartments. Eighteen LAB strains secreted molecules that curtailed the growth of H. pylori and the activity was urea-resistant in five LAB. Several LAB supernatants also reduced the urease activity of H. pylori. Pre-treatment of H. pylori with acidic LAB supernatants abrogated its flagella-mediated motility and decreased its ability to elicit pro-inflammatory IL-8 cytokine from human gastric cells, without reverting the H. pylori-induced repression of other pro-inflammatory cytokines. This study identified the LAB that have the most anti-H. pylori effects, decreasing its viability, its production of virulence factors, its motility and/or its ability to elicit pro-inflammatory IL-8 from gastric cells. Once identified, these molecules can be used as alternatives or complements to current antibiotics to fight H. pylori infections.